Pharmacogenomic Evaluation of Antihypertensive Responses 2

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 839 participants.

Also called NCT01203852

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 839 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01203852
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01203852. Allocation not applicable; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-05-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacogenomic Evaluation of Antihypertensive Responses 2
Acronym
PEAR2
Condition
Hypertension
Intervention (Drug)
Metoprolol
Intervention (Drug)
Chlorthalidone
Lead sponsor
University of Florida (class: other)
Collaborator
National Institute of General Medical Sciences (NIGMS) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01203852
Content hash
6f7f9c8bef9e7c30c139d7888577bee26eff69add667986de7011103a722fb7a